Par-4；GLP-1

UnknownPhase 4

Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 or Metformin Treatment

The Correlation Between Par-4 and Telomere-telomerase System in the New Dignosised Type 2 Diabetes Patients Who Received GLP-1 Analog or Metformin Treatment

Lead sponsor

Third Military Medical University

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Enrollment

200

estimated

Study population

Healthy volunteers, Type 2 diabetes

Key I/E criterion

•HbA1c ≥10%

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02535299

Org study IDGLP-1

Timeline

Milestones

Study first posted2015-08-28estimated

Last update posted2016-09-13estimated

Study start2016-06 (month precision)

Primary completion2018-12estimated (month precision)

Study completion2019-12estimated (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Healthy volunteersType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

Maximum age75 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Newly dignosised type 2 diabetes according to WHO criteria.glycated hemoglobin (HbA1c) was more than 10%;

•Seronegative for antibodies against insulin, islet cells and glutamic acid decarboxylase (GAD);

Exclusion criteria

•Type 1 diabetes mellitus,presence of autoimmune diabetes indicated by antibodies to insulin, islet cells, and GAD；

•Gestational diabetes;

•patients with heart, liver, or renal function impairment;presence of severe infections or cerebrovascular disease;

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)

Glycemic / diabetes

1 endpoint

Primary/protocol endpoint

physiological parameter:glycosylated hemoglobin A1c

Time frame:up to 6 months;

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Other (unclassified)

4 endpoints

Secondary/protocol endpoint/low confidence

physiological parameter:the concentration of Par-4

Time frame:up to 6 months;

concentration, descriptive

Secondary/protocol endpoint/low confidence

physiological parameter:telomere length

Time frame:up to 6 months;

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

physiological parameter:telomease activity

Time frame:up to 6 months;

descriptive

Secondary/protocol endpoint/low confidence

physiological parameter:TNF-α

Time frame:up to 6 months;

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.